Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis.
Okamura A, Yakushijin K, Inui Y, Funakoshi Y, Kawamori Y, Shimada T, Toyoda M, Chayahara N, Kiyota N, Fujiwara Y, Mukohara T, Matsuoka H, Yamamoto K, Minami H. Okamura A, et al. Among authors: kawamori y. Int J Hematol. 2011 Jun;93(6):765-770. doi: 10.1007/s12185-011-0852-5. Epub 2011 Apr 22. Int J Hematol. 2011. PMID: 21512728
Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation.
Okamura A, Yamamori M, Shimoyama M, Kawano Y, Kawano H, Kawamori Y, Nishikawa S, Minagawa K, Yakushijin K, Katayama Y, Sakaeda T, Hirai M, Matsui T. Okamura A, et al. Among authors: kawamori y. Int J Hematol. 2008 Jul;88(1):104-110. doi: 10.1007/s12185-008-0093-4. Epub 2008 May 14. Int J Hematol. 2008. PMID: 18473127 Clinical Trial.
Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease.
Nishikawa S, Okamura A, Yamamori M, Minagawa K, Kawamori Y, Kawano Y, Kawano H, Ono K, Katayama Y, Shimoyama M, Matsui T. Nishikawa S, et al. Among authors: kawamori y. Transplant Proc. 2009 Nov;41(9):3873-6. doi: 10.1016/j.transproceed.2009.06.231. Transplant Proc. 2009. PMID: 19917404
Progressive osteosclerosis and visceral calcification after cord blood transplantation.
Asada N, Ishii S, Wakahashi K, Kawano H, Kawamori Y, Nishikawa S, Minagawa K, Okamura A, Shimoyama M, Katayama Y, Hayashi Y, Itoh T, Tanimoto M, Matsui T. Asada N, et al. Among authors: kawamori y. Int J Hematol. 2010 Apr;91(3):542-5. doi: 10.1007/s12185-010-0524-x. Epub 2010 Feb 17. Int J Hematol. 2010. PMID: 20162469
Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation.
Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, Kawano H, Kawano Y, Kawamori Y, Sada A, Matsui T, Katayama Y. Wakahashi K, et al. Among authors: kawamori y. Int J Hematol. 2011 Aug;94(2):193-202. doi: 10.1007/s12185-011-0888-6. Epub 2011 Jul 14. Int J Hematol. 2011. PMID: 21751082
95 results